Workshops

MMRM’s kicking LOCF’s butt for repeated measures. Cluster trials are blowing up. Takeaway: Mixed models decode data.

R’s lme4, nlme, brms handle fixed effects, random effects, clustering. Takeaway: R makes messy data easy.

Lean into MMRM, nail clustering for clear insights from chaotic designs. Takeaway: Right model, right insights.

A mental health trial used lme4 to dig up treatment effects in clusters. Takeaway: Mixed models turn noise to signal. An

Mixed Models for Repeated Measures (MMRM) outperform traditional methods like LOCF by handling missing and correlated da

DSMBs leveling up, alpha-spending makes interim calls sharp. Takeaway: Monitoring’s the guardian angel.

DMC charters, boundary-tracking tools keep blinded or unblinded monitoring smooth. Takeaway: Tools make oversight a bree

Mix blinded/unblinded with alpha-spending to keep trials clean. Takeaway: Smart monitoring saves the day.

A heart drug trial’s DSMB made a clutch interim call, saving lives. Takeaway: Oversight’s where science gets real. Analy

Effective monitoring through DSMBs and DMCs ensures participant safety and maintains trial integrity. Alpha-spending and

MCAR, MAR, MNAR—puzzle pieces you can solve. Imputation’s stealing the spotlight in trials. Takeaway: Know gaps to keep

R’s mice, smcfcs, mitml make imputation and stress-testing a breeze. Takeaway: R’s your data-fix weapon.

Mix imputation with sensitivity checks to make FDA/EMA nod. Bulletproof your trial. Takeaway: Impute, test, win.

A vaccine trial beat 20% missing data with MICE, passing EMA scrutiny. Epic comeback. Takeaway: You got this. Analytics

Understanding MCAR, MAR, and MNAR is essential to choose the right imputation method and avoid bias. R packages like M

ICER, QALY are buzzwords for drug worth. Economic evaluations are a trial must-do. Takeaway: Money talks, learn the ling

Decision trees, Markov models, sensitivity tools turn numbers into payer-friendly stories. Takeaway: Models sell the big

Craft data-driven models, test hard to win budget folks and policymakers. Takeaway: Solid models mean wins.

A diabetes drug trial’s Markov model proved it was a steal, changing patient lives. Takeaway: Economics makes or breaks

ICER (Incremental Cost-Effectiveness Ratio) and QALY (Quality-Adjusted Life Year) are core tools for assessing a drug’s